



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|---------------------------|------------------------------|------------|---------------|
| Application No.: | 10/717,738 | Art Unit: | 1614 |
| Filed: | November 20, 2003 | Examiner: | K. Weddington |
| 1 st Inventor: | H. Odaka | Allowed: | |
| For: | Agent for Improving Acidosis | Batch: | |
| Atty. Dkt. No. | 2596 US1P | Paper No.: | |

Supplemental Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached form PTO-1449 under §1.97(b).

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call Applicants' attorney.


Respectfully submitted,

Dated: November 2, 2006

(224) 554-5689
(224) 554-5494

Elaine M. Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
One Takeda Parkway
Deerfield, IL 60015 USA



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|-----------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/717,738 | | |
| | | Filing Date | November 20, 2003 | | |
| | | First Named Inventor | H. Odaka | | |
| | | Art Unit | 1614 | | |
| | | Examiner Name | K. Weddington | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | 2596 US1P |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | SUZUKI, M., et al., "Effects of Combined Pioglitazone and Metformin on Diabetes and Obesity in Wistar Fatty Rats", Clinical and Experimental Pharmacology and Physiology, (2002), Vol. 29, pages 269-274 | |
| | | The Merck Manual of Diagnosis and Therapy, (1999), pages 176-179 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.